Fintech

AstraZeneca Confident Rare-Disease Drug Can Hit Target After Mixed Study Results

Wsj·March 31, 2026 at 12:23 PM

The company said the results support the drug’s potential to transform the treatment of hypophosphatasia and it plans to submit data to regulators as soon as possible.

Original Source

Wsj — www.wsj.com

Related in Fintech

Monzo US retreat shows neobank expansion struggles
PYMNTS
Oracle Cuts Thousands of Jobs Amid Stock Decline
PYMNTS
Anthropic Tests Advanced AI Model, Claude Mythos
PYMNTS
Bitcoin enters public bond market with Moody's rating
CoinDesk

AstraZeneca Confident Rare-Disease Drug Can Hit Target After Mixed Study Results

Monzo US retreat shows neobank expansion struggles

Oracle Cuts Thousands of Jobs Amid Stock Decline

Anthropic Tests Advanced AI Model, Claude Mythos

Bitcoin enters public bond market with Moody's rating